Cargando…

Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy

BACKGROUND: The treatment of high-risk neuroblastoma patients consists of multimodal induction therapy to achieve remission followed by consolidation therapy to prevent relapses. However, the type of consolidation therapy is still discussed controversial. We applied metronomic chemotherapy in the pr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Simon, Thorsten, Hero, Barbara, Faldum, Andreas, Handgretinger, Rupert, Schrappe, Martin, Klingebiel, Thomas, Berthold, Frank
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3031264/ https://www.ncbi.nlm.nih.gov/pubmed/21244693 http://dx.doi.org/10.1186/1471-2407-11-21

Ejemplares similares

IMMU-02. CH14.18 IN THE TREATMENT OF HIGH-RISK NEUROBLASTOMA: A META-ANALYSIS
por: Abdel-Khaleq, Sameerah, et al.
Publicado: (2021)

Immunomonitoring of Stage IV Relapsed Neuroblastoma Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation and Subsequent GD2 (ch14.18/CHO) Antibody Treatment
por: Seitz, Christian Martin, et al.
Publicado: (2021)

Long-term continuous infusion of anti-GD2 antibody CH14.18/CHO in relapsed/refractory neuroblastoma patients
por: Lode, Holger, et al.
Publicado: (2013)

Functional Bioassays for Immune Monitoring of High-Risk Neuroblastoma Patients Treated with ch14.18/CHO Anti-GD(2) Antibody
por: Siebert, Nikolai, et al.
Publicado: (2014)

Comparative pharmacokinetics, safety, and tolerability of two sources of ch14.18 in pediatric patients with high-risk neuroblastoma following myeloablative therapy
por: Marachelian, Araz, et al.
Publicado: (2016)

Tolerability, response and outcome of high-risk neuroblastoma patients treated with long-term infusion of anti-GD(2) antibody ch14.18/CHO
por: Mueller, Ina, et al.
Publicado: (2017)

The Premalignant Ancestor Cell of t(14;18)(+) Lymphoma
por: Brisou, Gabriel, et al.
Publicado: (2021)

Reduction of CD11b(+) myeloid suppressive cells augments anti-neuroblastoma immune response induced by the anti-GD(2) antibody ch14.18/CHO
por: Siebert, Nikolai, et al.
Publicado: (2020)

Targeting GD2 after allogeneic SCT: effector cell composition defines the optimal use of ch14.18 and the bispecific antibody construct NG-CU (GD2-CD3)
por: Arendt, A.-M., et al.
Publicado: (2023)

The clinical and molecular taxonomy of t(14;18)-negative follicular lymphomas
por: Salaverria, Itziar, et al.
Publicado: (2023)

Chimeric Antibody c.8B6 to O-Acetyl-GD2 Mediates the Same Efficient Anti-Neuroblastoma Effects as Therapeutic ch14.18 Antibody to GD2 without Antibody Induced Allodynia
por: Terme, Mickaël, et al.
Publicado: (2014)

Effective combination treatment of GD2-expressing neuroblastoma and Ewing's sarcoma using anti-GD2 ch14.18/CHO antibody with Vγ9Vδ2+ γδT cells
por: Fisher, Jonathan P H, et al.
Publicado: (2015)

Correction: Chimeric Antibody c.8B6 to O-Acetyl-GD2 Mediates the Same Efficient Anti-Neuroblastoma Effects as Therapeutic ch14.18 Antibody to GD2 without Antibody Induced Allodynia
Publicado: (2014)

Long-term outcomes of the GPOH NB97 trial for children with high-risk neuroblastoma comparing high-dose chemotherapy with autologous stem cell transplantation and oral chemotherapy as consolidation
por: Berthold, Frank, et al.
Publicado: (2018)

Correction: Long-term outcomes of the GPOH NB97 trial for children with high-risk neuroblastoma comparing high-dose chemotherapy with autologous stem cell transplantation and oral chemotherapy as consolidation
por: Berthold, Frank, et al.
Publicado: (2019)

Impact of HACA on Immunomodulation and Treatment Toxicity Following ch14.18/CHO Long-Term Infusion with Interleukin-2: Results from a SIOPEN Phase 2 Trial
por: Siebert, Nikolai, et al.
Publicado: (2018)

Acquired resistance to venetoclax (ABT-199) in t(14;18) positive lymphoma cells
por: Bodo, Juraj, et al.
Publicado: (2016)

Relapse of follicular lymphoma arising from a non‐t(14;18) clone
por: Otsuka, Yasuyuki, et al.
Publicado: (2020)

Correlation of t(14;18) translocation breakpoint site with clinical characteristics in follicular lymphoma
por: Panjan, Matej, et al.
Publicado: (2023)

Pre-existing antitherapeutic antibodies against the Fc region of the hu14.18K322A mAb are associated with outcome in patients with relapsed neuroblastoma
por: Goldberg, Jacob L, et al.
Publicado: (2020)

Correction: Pre-existing antitherapeutic antibodies against the Fc region of the hu14.18K322A mAb are associated with outcome in patients with relapsed neuroblastoma
Publicado: (2020)

Translocation t(14;18) in B cell lymphomas as a cause for defective immunoglobulin production
Publicado: (1989)

Detection of a second t(14;18) breakpoint cluster region in human follicular lymphomas
Publicado: (1986)

Composite t(14;18)-Negative Follicular Lymphoma and Nodular Lymphocyte-Predominant Hodgkin Lymphoma
por: O'Neill, John Patrick, et al.
Publicado: (2018)

Occupational exposure to pesticides and occurrence of the chromosomal translocation t(14;18) among farmers in Jordan
por: Qaqish, Bara’a M., et al.
Publicado: (2016)

Metronomic chemotherapy
por: Maiti, Rituparna
Publicado: (2014)

Metronomic Chemotherapy
por: Cazzaniga, Marina Elena, et al.
Publicado: (2021)

Evaluation of bcl-2 protein expression and 14;18 translocation as prognostic markers in follicular lymphoma.
por: Pezzella, F., et al.
Publicado: (1992)

High frequency of t(14;18) translocation in salivary gland lymphomas from Sjogren's syndrome patients
Publicado: (1991)

Apoptosis of t(14;18)-positive lymphoma cells by a Bcl-2 interacting small molecule
por: Abbott, David R., et al.
Publicado: (2009)

Presence of t(14;18) translocation in healthy individuals varies according to ethnic background in the Brazilian population
por: Levy, D., et al.
Publicado: (2017)

Follicular lymphoma subgroups with and without t(14;18) differ in their N-glycosylation pattern and IGHV usage
por: Leich, Ellen, et al.
Publicado: (2021)

Low CD4⁺/CD25⁺/CD127⁻ regulatory T cell- and high INF-γ levels are associated with improved survival of neuroblastoma patients treated with long-term infusion of ch14.18/CHO combined with interleukin-2
por: Troschke-Meurer, Sascha, et al.
Publicado: (2019)

Antibody–drug conjugates, cancer immunotherapy, and metronomic chemotherapy as novel approaches in cancer management
por: Sarangi, Sudhir Chandra, et al.
Publicado: (2020)

Chronic Lymphocytic Leukemia with t(14;18)(q32;q21) As a Sole Cytogenetic Abnormality
por: Elyamany, Ghaleb, et al.
Publicado: (2014)

An unusual case of chronic lymphocytic leukemia with trisomy 12 and t(14;18) and a favorable response to ibrutinib
por: Haddad, Fady Gh, et al.
Publicado: (2021)

Formation of a G-quadruplex at the BCL2 major breakpoint region of the t(14;18) translocation in follicular lymphoma
por: Nambiar, Mridula, et al.
Publicado: (2011)

Dicentric Chromosome 14;18 Plus Two Additional CNVs in a Girl with Microform Holoprosencephaly and Turner Stigmata
por: Sireteanu, A, et al.
Publicado: (2013)

Isolated Follicles Enriched for Centroblasts and Lacking t(14;18)/BCL2 in Lymphoid Tissue: Diagnostic and Clinical Implications
por: Nybakken, Grant E., et al.
Publicado: (2016)

Molecular Classification Substitutes for the Prognostic Variables Stage, Age, and MYCN Status in Neuroblastoma Risk Assessment
por: Rosswog, Carolina, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_219va5lph768995af6td5m7p93